A Phase II Study to Evaluate Lenalidomide in Combination With Metronomic-Dose Cyclophosphamide in Patients With Heavily Pretreated Classical Hodgkin Lymphoma

Acta Oncologica - United Kingdom
doi 10.3109/0284186x.2015.1007212
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Informa UK Limited

Related search

High Response Rates and Safe Toxic Profile of Brentuximab Vedotin/Bendamustine Combination in Heavily Pretreated Patients With Relapsed/Refractory Hodgkin Lymphoma (HL)

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2017English

Carboplatin in Combination With Epirubicin and Cyclophosphamide in Patients With Advanced Ovarian Cancer: A Phase II Study

Acta Oncologica
Nuclear MedicineRadiologyHematologyOncologyMedicineImaging
1995English

Targeting Tumor-Related Immunosuppression Using Metronomic Cyclophosphamide in Combination With Lenalidomide -New Mechanisms for Old Drugs

Chemotherapy: Open Access
2012English

A Phase II Study of Bendamustine in Combination With Rituximab as Initial Treatment for Patients With Indolent Non-Follicular Non-Hodgkin Lymphoma

Leukemia and Lymphoma
Cancer ResearchOncologyHematology
2016English

Combination of Nivolumab and Bendamustine in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2019English

A Phase Ii Study of Lenalidomide and Rituximab (R²) Combination in Patients With High-Risk Refractory/Relapsed Diffuse Large B-Cell Lymphoma

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2019English

An Uncommon Response to Metronomic Therapy in a Heavily Pretreated Patient With Metastatic Carcinosarcoma: A Case Report

Journal of Medical Case Reports
Medicine
2016English

Phase I/Ii Study of 2-Chloro-2′-Deoxyadenosine With Cyclophosphamide in Patients With Pretreated B Cell Chronic Lymphocytic Leukemia and Indolent Non-Hodgkin’s Lymphoma

Leukemia
Cancer ResearchOncologyAnesthesiologyPain MedicineHematology
2000English

A Dose-Escalating Phase I of Imatinib Mesylate With Fixed Dose of Metronomic Cyclophosphamide in Targeted Olid Tumours

British Journal of Cancer
Cancer ResearchOncology
2013English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy